Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
18.06. | Fired ACIP panel says RFK Jr is weakening vaccine programmes | ||
18.06. | UK regulator overhauls medical device regulation | ||
18.06. | Welsh biotech Draig emerges with $140m in financing | ||
18.06. | FDA unveils fast-track review path for 'national priorities' | ||
17.06. | 23andMe fined £2.31m over UK users' genetic data breach | ||
17.06. | FDA green lights CSL's once-monthly HAE drug Andembry | ||
17.06. | Update: Rumour confirmed as Lilly buys Verve Therapeutics | ||
17.06. | Caris swells its planned IPO, seeking $5.7bn valuation | ||
17.06. | Is Lilly about to swoop on Verve Therapeutics? | ||
17.06. | Genentech's Bittenbender named board chair at BIO | ||
16.06. | After rebuffing Biogen, Sage pairs off with Supernus | ||
16.06. | J&J says two drugs are better than one in pretreated myeloma | ||
16.06. | Former CEO wins bidding war for 23andMe, beating Regeneron | ||
16.06. | DMD gene therapy Elevidys linked to new liver failure case | ||
16.06. | Streeting pledges clinical trial signups in the NHS App | ||
13.06. | US lawmakers seek ban on DTC advertising | ||
13.06. | AZ taps Chinese firm CSPC's AI acumen in $5.2bn+ alliance | ||
13.06. | Moderna's RSV shot gets US nod for use in younger adults | ||
13.06. | Pushback rises against RFK Jr's new ACIP membership | ||
13.06. | NHS starts first national rollout of Blenrep for myeloma | ||
13.06. | Data at EULAR back Biogen, UCB's first-in-class lupus drug | ||
12.06. | BioNTech to buy rival mRNA firm CureVac for $1.25bn | ||
12.06. | MSD aims to plug dengue fever vaccine gap in US | ||
12.06. | FDA clears Nuvation's first product Ibtrozi, for lung cancer | ||
12.06. | Novo Nordisk teams up with NVIDIA on AI models |